Given Imaging landed a win in Japan for its bite-sized pill camera used to detect colon disease. The PillCam Colon was cleared for sale this week by the island nation’s Pharmaceuticals & Medical Devices Agency and could expand the company’s Japanese market reach 10-fold, according to a press release.
Ocular Therapeutix said it closed a $23.8 million Series D extension round from existing backers for its sustained drug release technology to treat eye diseases.
The Bedford, Mass.-based medical device company said all of its current institutional investors ponied up for the round, including Polaris Ventures, Versant Ventures, SV Life Sciences, Sparta LLC, and Ascension Health Ventures.
Ocular Therapeutix is developing a punctum plug for the entry of the tear duct to release drug therapy to the surface of the eye over several months.
STJ shares closed up 1.5% yesterday at $38.85 each after St. Jude revealed the warning letter, but closed down 1.2% today at $38.39 apiece.
Given Imaging submitted for FDA approval its PillCam Colon 2 capsules endoscopy system, a device designed for the visualization of the colon.
The Israel-based company hopes to get the FDA nod through the federal watchdog agency’s de novo approval pathway.
Given Imaging saw moderate growth in revenue during its 3rd quarter, and posted a 60% increase in net income.
The Israel-based medical device maker posted $6 million in profit, or 19¢ per share on sales of $45.4 million for the 3 months ended Sept. 30. That compared with a net income of $3.8 million, or 12¢ per share on sales of $44.7 million during the same period last year.
Nanostim, the Sunnyvale, Calif.-based company that’s developing a leadless pacemaker, raised $10 million in an equity and options deal, according to a regulatory filing.
San Diego-based NuVasive, which makes spinal surgery implants, said 3rd-quarter sales will be about $147 million, 4.8% below the roughly $154.4 million the company expected to post.